Angiotensin receptor blockers = angiotensin converting enzyme inhibitors minus dry cough?

Authors

  • Ashwin Kamath Department of Pharmacology, Kasturba Medical College, Manipal University, Mangaluru, Karnataka, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20150399

Keywords:

Angiotensin receptor blockers, Angiotensin converting enzyme inhibitors

Abstract

Blockade of the renin angiotensin aldosterone system (RAAS) is an important pharmacological intervention in cardiovascular (CV) diseases. Hypertension, heart failure (HF) and myocardial infarction are important indications for use of angiotensin converting enzyme inhibitors (ACEIs), which potentially decrease morbidity and prolong survival. Dry cough is an important adverse effect seen in about 20% of the patients which might require discontinuation of the drug. In such situations, angiotensin receptor blockers (ARBs) serve as replacement drugs in all the indications, as they are largely devoid of this limiting adverse effect.

References

Hilal-Dandan R. Renin and angiotensin. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 12th Edition. China: McGraw-Hill Companies, Inc.; 2011.

James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-20.

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128(16):e240-327.

Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64:e139-228.

O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):e78-140.

van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33(16):2088-97.

Savarese G, Costanzo P, Cleland JG, Vassallo E, Ruggiero D, Rosano G, Perrone-Filardi P. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol. 2013;61(2):131-42.

Cheng J, Zhang W, Zhang X, Han F, Li X, He X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014;174(5):773-85.

Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2014;(8):CD009096.

Xue H, Lu Z, Tang WL, Pang LW, Wang GM, Wong GW, et al. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev. 2015;(1):CD008170.

Downloads

Published

2017-01-19

How to Cite

Kamath, A. (2017). Angiotensin receptor blockers = angiotensin converting enzyme inhibitors minus dry cough?. International Journal of Basic & Clinical Pharmacology, 4(4), 813–814. https://doi.org/10.18203/2319-2003.ijbcp20150399

Issue

Section

Letter to the Editor